Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Several other research firms have also commented on SYRS. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Stock Down 0.9 %

Syros Pharmaceuticals stock opened at $0.20 on Monday. The company has a market capitalization of $5.37 million, a P/E ratio of -0.07 and a beta of 1.33. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. Syros Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The stock has a 50-day simple moving average of $1.17 and a 200-day simple moving average of $2.86.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the previous year, the company posted ($1.35) EPS. Equities research analysts expect that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Certuity LLC purchased a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $109,000. Acadian Asset Management LLC grew its holdings in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.